Recro Gainesville Drug Patent Portfolio
Recro Gainesville owns 1 orange book drug protected by 18 US patents Given below is the list of Recro Gainesville's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10092559 | Abuse resistant pharmaceutical compositions | 12 Sep, 2034 | Active |
| US9132096 | Abuse resistant pharmaceutical compositions | 12 Sep, 2034 | Active |
| US9452163 | Abuse resistant pharmaceutical compositions | 12 Sep, 2034 | Active |
| US9486451 | Abuse resistant pharmaceutical compositions | 12 Sep, 2034 | Active |
| US9713611 | Abuse resistant pharmaceutical compositions | 12 Sep, 2034 | Active |
| US10028946 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US10322120 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US10456393 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US10722511 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US9265760 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US9326982 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US9333201 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US9339499 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US9421200 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US9433619 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US9610286 | Treating pain in patients with hepatic impairment | 25 Jul, 2033 | Active |
| US6228398 | Multiparticulate modified release composition | 01 Nov, 2019 | Expired |
| US6902742 | Multiparticulate modified release composition | 01 Nov, 2019 | Expired |
Latest Legal Activities on Recro Gainesville's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Recro Gainesville.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US9486451 |
|
Maintenance Fee Reminder Mailed
Critical
| 20 May, 2024 | US9452163 |
|
Maintenance Fee Reminder Mailed
Critical
| 29 Apr, 2024 | US9433619 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Apr, 2024 | US9421200 |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Mar, 2024 | US10722511 |
|
Expire Patent
Critical
| 04 Dec, 2023 | US10456393 |
|
Expire Patent
Critical
| 24 Jul, 2023 | US10322120 |
|
Maintenance Fee Reminder Mailed
Critical
| 19 Jun, 2023 | US10456393 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Mar, 2023 | US9132096 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 06 Feb, 2023 | US10322120 |
|
Expire Patent
Critical
| 29 Aug, 2022 | US10028946 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Apr, 2022 | US10092559 |
| Surcharge for Late Payment, Large Entity | 20 Apr, 2022 | US10092559 |
|
Maintenance Fee Reminder Mailed
Critical
| 14 Mar, 2022 | US10028946 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jan, 2021 | US9713611 |
Recro Gainesville's Family Patents
Recro Gainesville drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 47.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Recro Gainesville Drug List
Given below is the complete list of Recro Gainesville's drugs and the patents protecting them.
1. Zohydro Er
Zohydro Er is protected by 18 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10092559 | Abuse resistant pharmaceutical compositions |
12 Sep, 2034
(9 years from now)
| Active |
| US9132096 | Abuse resistant pharmaceutical compositions |
12 Sep, 2034
(9 years from now)
| Active |
| US9452163 | Abuse resistant pharmaceutical compositions |
12 Sep, 2034
(9 years from now)
| Active |
| US9486451 | Abuse resistant pharmaceutical compositions |
12 Sep, 2034
(9 years from now)
| Active |
| US9713611 | Abuse resistant pharmaceutical compositions |
12 Sep, 2034
(9 years from now)
| Active |
| US10028946 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US10322120 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US10456393 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US10722511 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US9265760 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US9326982 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US9333201 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US9339499 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US9421200 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US9433619 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US9610286 | Treating pain in patients with hepatic impairment |
25 Jul, 2033
(8 years from now)
| Active |
| US6228398 | Multiparticulate modified release composition |
01 Nov, 2019
(5 years ago)
| Expired |
| US6902742 | Multiparticulate modified release composition |
01 Nov, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zohydro Er's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List